Despite positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from PBMs. The companies are typically building obstacles to access, including steep expense restrictions and PA that limit patient opportunity. Market indicate that the coverage challenge